白台瑞(Thierry Pierre Robert Burnouf)　教授

Email
thierry@tmu.edu.tw
現   職
生醫材料暨組織工程研究所 教授
醫學工程學院 副院長

學經歷

學　歷

畢業學校與學位[修業時間]
Lille UniversityBiochemistry 博士
1977/09~1981/05
Lille UniversityBiochemistry 碩士
1976/09~1977/07
Lille UniversityBiology 學士
1972/09~1976/07

本校學術經歷

任職單位與職稱[起迄時間]
生醫材料暨組織工程研究所教授
2015/08/01~
生醫材料暨組織工程研究所(舊)教授
2012/08/01~2015/07/31

本校兼職教學行政經歷

服務單位與職稱[起迄時間]
心智意識與腦科學研究博士學位學程教授
2020/01/01 ~
(舊)細胞治療與再生醫學國際博士學位學程籌備處教授
2018/02/01 ~
醫學工程學院副院長
2017/10/05 ~
國際生醫工程博士學位學程主任
2016/08/01 ~ 2022/07/31
生醫材料暨組織工程研究所所長
2015/08/01 ~ 2018/05/31
生醫材料暨組織工程研究所(舊)所長
2013/08/01 ~ 2015/07/31

其它經歷

任職單位與職稱[起迄時間]
Human Plasma Product ServiceDirector
Naemonetics Corporation,Boston,Ma.,USAVice President
1995/10~1997/12
Laboratoire Francais du Fractionnement et des BiotechnologiesGeneral Manager
1994/06~1995/10
Regional Blood Transfusion CenterHead
1987/09~1995/10
Regional Blood Transfusion CenterHead
1984/10~1986/10

專長與研究領域

學門領域
醫學之生化及分子生物
學術專長
chromatography
electrophoresis
cell cultures
western blot
solvent-detergent and pasteurisation for viral inactivation
nanofiltration for virus removal
coagulation assays
Elisa

論文著作

清冊下載

論文 Journal Paper


1. 2024 Lin Jia Cheng,Kaswan Kuldeep,Chatterjee Subhodeep,Wu Yu Wen,Kumar Sharma Manish,Ranjan Ashok,Roy Barman Snigdha,Lin Yu Zih,Burnouf Thierry,Boireau Wilfrid,Lu Ming Yen,Tu Yong Kwang,Su I. Chang,Wu Ping Hsiu,Lin Zong Hong,Fan Yu Jui,Lin Jia Cheng,Kaswan Kuldeep,Chatterjee Subhodeep,Wu Yu Wen,Kumar Sharma Manish,Ranjan Ashok,Roy Barman Snigdha,Lin Yu Zih,Burnouf Thierry,Boireau Wilfrid,Lu Ming Yen,Tu Yong Kwang,Su I. Chang,Wu Ping Hsiu,Lin Zong Hong,Fan Yu Jui. CuO NWs boosted triboelectric microfluidic nanosensor functionalized by collagen-protein interactions for real-time platelet count monitoring . Chemical Engineering Journal .2024 ;(490)

2. 2024 CuO NWs boosted triboelectric microfluidic nanosensor functionalized by collagen-protein interactions for real-time platelet count monitoring . Chemical Engineering Journal .2024 ;(490)

3. 2023 Hao PC,Burnouf T,Chiang CW,Jheng PR,Szunerits S,Yang JC, Chuang EY. Enhanced Diabetic Wound Healing Using Platelet-Derived Extracellular Vesicles and Reduced Graphene Oxide in Polysaccharide-Coordinated Hydrogels . Journal of Nanobiotechnology .2023 ;(21):1-17

4. 2023 Burnouf T,Chou ML,Lundy DJ,Chuang EY,Tseng CL,Goubran H. Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery . Journal of Biomedical Science .2023 ;(30):1-34

5. 2023 Khalil A,Barras A,Boukherroub R,Tseng CL,Devos D,Burnouf T, Neuhaus W, Szunerits S. Enhancing paracellular and transcellular permeability using nanotechnological approaches for the treatment of brain and retinal diseases . Nanoscale Horizons .2023

6. 2023 Wu YH,Chao HS,Chiang CL,Luo YH,Chiu CH,Yen SH, Liu CY, Chiou JF, Burnouf T, Chen YJ, Wang PY, Chao TY, Hsu SM, Lu LS. Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell-derived organoids . Thorac Cancer .2023 ;(14):2591-2600

7. 2023 Kumar P,Pandith A,Tseng CT,Burnouf T. Recent Developments in Mitochondrial G-Quadruplex Recognising Fluorescent Probes: A Review . Journal of Photochemistry & Photobiology, C: Photochemistry Reviews .2023 ;(56):1-39

8. 2023 Wu YW,Lee DY,Lu YL,Delila L,Nebie O,Barro L, Changou CA, Lu LS, Goubran H, Burnouf T. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: Preparation and in vitro characterization . Platelets .2023 ;(34):1-12

9. 2023 Chou ML,Babamale OA,Walker T,Cognasse F,Blum D,Burnouf T. Blood-brain crosstalk: the roles of neutrophils, platelets, and neutrophil extracellular traps in neuropathologies . Trends in Neurosciences .2023 ;(46):764-779

10. 2023 McIntosh D,Burnouf T,Karbiener M,Farcet MR,Kreil TR. Prevention and treatment of COVID-19 by mono- and poly-clonal antibodies . Blood Transfusion .2023 ;(21):375-377

11. 2023 Liu YW,Burnouf T,Chang CY,Chen SH,Chen YJ,Chen YH, Ho WL, Liao YM, Lin PC, Liu YL, James S Miser, Wang JL, Wang PY, Wang SC, Wong TT, Wu SP, Wu YH, Chiou JF, Lu LS . Treatment response prediction with circulating tumor cell-derived organoids for soft tissue sarcoma . Journal of Clinical Oncology .2023 ;(41):e23521-e23521

12. 2023 Gabriel C,Marks DC,Henschler R,Schallmoser K,Burnouf T,Koh MBC. Eye drops of human origin-Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies . Vox Sanguinis .2023 ;(118):301-309

13. 2023 Shouman M,Goubran H,Seghatchian J,Burnouf T. Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient's safety and survival outcome:A systematic narrative appraisal of where we are now! . Transfusion & Apheresis Science .2023 ;(62):1-6

14. 2023 Chen YT,Liu CH,Pan WY,Jheng PR,Hsieh YSY,Burnouf T, Fan YJ, Chiang CC, Chen TY, Chuang EY. Biomimetic Platelet Nanomotors for Site-Specific Thrombolysis and Ischemic Injury Alleviation . ACS Applied Materials & Interfaces .2023 ;(15):32967-32983

15. 2023 Burnouf T,Epstein J,Faber JC,WM Smid. Stepwise options for preparing therapeutic Plasma proteins from domestic plasma in low- and middle-income countries . Vox Sanguinis .2023

16. 2022 Al-Riyami AZ,Burnouf T,Wood EM,Devine VD,Oreh A,Apelseth TO, et al. International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic . Vox Sanguinis .2022 ;(117):822-830

17. 2022 Burnouf T,Epstein J,Faber JC,Smid M. Stepwise access to safe plasma proteins in resource-constrained countries: Local production and pathways to fractionation-Report of an International Society of Blood Transfusion Workshop . Vox Sanguinis .2022 ;(117):789-795

18. 2022 Focosi D,Franchini M,Pirofski LA,Burnouf T,Paneth N,Joyner MJ, Casadevall A. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes . Clinical Microbiology Reviews .2022 ;(35):1-29

19. 2022 Burnouf T,Jheng PR,Chen YH,Rethi L,Rethi L,Lu LS, Ho YC, Chuang EY. Near-infrared-driven photoablation of lung cancer tumors utilizing biomimetic platelet-polyethyleneimine-polypyrrole drug-free nanoparticles . Materials & Design .2022 ;(215):1-12

20. 2022 Hartmann J,Bloch EM,Burnouf T. Experience with COVID-19 convalescent plasma provides vital guidance to future pandemics . Transfusion .2022 ;(62):681-684

21. 2022 Burnouf T,Goubran HA. Regenerative effect of expired platelet concentrates in human therapy: An update . Transfusion & Apheresis Science .2022 ;(61):1-3

22. 2022 Wu Y-H,Hung Y-P,Chiu N-C,Lee R-C,Li C-P,Chao Y, Shyr Y-M, Wang S-E, Chen S-C, Lin S-H, Chen Y-H, Kang Y-M, Hsu S-M, Yen S-H, Wu J-Y, Lee K-D, Tseng H-E, Tsai J-R, Tang J-H, Chiou J-F, Burnouf T, Chen Y-J, Wang P-Y, Lu L-S*. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma . European Journal of Cancer .2022 ;(166):208-218

23. 2022 Belem WF,Liu C-H,Hu Y-T,Burnouf T,Lin L-T. Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2) . Viruses-Basel .2022 ;(14)

24. 2022 Holmberg JA,Henry SM,Burnouf T,Devine D,Marschner S,et al.. National Blood Foundation 2021 Research and Development summit: Discovery, innovation, and challenges in advancing blood and biotherapies . Transfusion .2022

25. 2022 Goubran H,Stakiw J,Seghatchian J,Ragab G,Burnouf T. SARS-CoV-2 and cancer: the intriguing and informative cross-talk . Transfusion & Apheresis Science .2022 ;(61):1-4

26. 2022 Goubran H,Seghatchian J,Sabry W,Ragab G,Burnouf T. Platelet and extracellular vesicles in COVID-19 infection and its vaccines . Transfusion & Apheresis Science .2022 ;(61)

27. 2022 Burnouf T,Gathof B,Bloch EM,Bazin R,Angelis VD,et al. Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2 . Transfusion Medicine Reviews .2022 ;(36):125-132

28. 2022 Burnouf T,Epstein J,Faber JC,Tayou Tagny C,Somuah D,Smid WM. Rationale for supporting stepwise access to safe plasma proteins through local production in low- and middle-income countries: A commentary of an international workshop . Biologicals .2022 ;(79):27-30

29. 2022 Widyaningrum R,Wu YW,Delila L,Lee DY,Wang TJ,Burnouf T. In vitro evaluation of platelet extracellular vesicles (PEVs) for corneal endothelial regeneration . Platelets .2022 ;(33):1237-1250

30. 2022 Burnouf T,Walker T. The multifaceted role of platelets in mediating brain function . Blood .2022 ;(140):815-827

31. 2022 Nebie O,Buée L,Blum D,Burnouf T. Can the administration of platelet lysates to the brain help treat neurological disorders? . Cellular & Molecular Life Sciences .2022 ;(79)

32. 2022 Delila L,Nebie O,Le N-T-N,Barro L,Chou M-L,Wu Y-W, Watanabe N, Takahara M, Buée L, Blum D, Devos D, Burnouf T. Neuroprotective activity of a virus-safe nanofiltered human platelet lysate depleted of extracellular vesicles in Parkinson's disease and traumatic brain injury models . Bioengineering & Translational Medicine .2022 ;(8):1-15

33. 2022 Gouel F,Timmerman K,Gosset P,Raoul C,Dutheil M,Jonneaux A, Garçon G, Moreau C, Danel-Brunaud V, Duce J, Burnouf T, Devedjian J-C, Devos D. Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis. . Biomaterials .2022 ;(280)

34. 2021 Nyam-Erdene A,Nebie O,Delila L,Buée L,Devos D,Chou S-Y, Blum D, Burnouf T. Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine . ACS Biomaterials Science & Engineering .2021 ;(7):5823-5835

35. 2021 Widyaningrum R,Burnouf T,Nebie O,Delila L,Wang TJ. A purified human platelet pellet lysate rich in neurotrophic factors and antioxidants repairs and protects corneal endothelial cells from oxidative stress . Biomedicine & Pharmacotherapy .2021 ;(142)

36. 2021 Lin KC,Ting LL,Chang CL,Lu LS,Lee HL,Hsu FC, Chiou JF, Wang PY, Burnouf T, Ho DC, Yang KC, Chen CY, Chen CH, Wu CZ, Chen YJ . Ex Vivo Expanded Circulating Tumor Cells for Clinical Anti-Cancer Drug Prediction in Patients with Head and Neck Cancer . Cancers (Basel) .2021 ;(13)

37. 2021 Focosi D,Franchini M,Pirofski L-A,Burnouf T,Paneth N,J. Joyner M, Casadevall A. COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy . MedRxiv .2021

38. 2021 Widyaningrum R,Burnouf T,Nebie O,Delila L,Wang TJ. A purified human platelet pellet lysate rich in neurotrophic factors and antioxidants repairs and protects corneal endothelial cells from oxidative stress . Biomedicine & Pharmacotherapy .2021 ;(142):1-15

39. 2021 Nebie Ouada,Barro Lassina,Wu Yu-Wen,Knutson Folke,Buee Luc,Devos David, Peng Chih-Wei, Blum David, Burnouf Thierry. Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro. . Platelets .2021 ;(32):226-237

40. 2021 Johnson J,Wu Y-W,Blyth C,Lichtfuss G,Goubran H,Burnouf T. Prospective Therapeutic Applications of Platelet Extracellular Vesicles. . Trends in Biotechnology .2021 ;(39):598-612

41. 2021 Liu Cheng-Sheng,Tsai Jia-Ruey,Kao Yi-Tzu,Lu Long-Sheng,Chen Yin-Ju,Burnouf Thierry, Wang Peng-Yuan, Chiou Jeng-Fong, Ting Lai-Lei. Chemoradiotherapy for Inoperable Carotid Body Leiomyosarcoma: A Case Report and Review of Literature. . Frontiers in Oncology .2021 ;(10)

42. 2021 Wendel Silvano,Land Kevin,Devine Dana V.,Daly James,Bazin Renee,Tiberghien Pierre, Lee Cheuk-Kwong, Arora Satyam, Patidar Gopal K., Khillan Kamini, Smid Willem Martin, Vrielink Hans, Oreh Adaeze, Al-Riyami Arwa Z., Hindawi Salwa, Vermeulen Marion, Louw Vernon, Burnouf Thierry, Bloch Evan M., Goel Ruchika, Townsend Mary, So-Osman Cynthia. Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic . Vox Sanguinis .2021 ;(116):872-879

43. 2021 Daniele Focosi,Massimo Franchini,Liise-anne Pirofski,Thierry Burnouf,DeLisa Fairweather,Michael J. Joyner, Arturo Casadevall. COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors . Viruses-Basel .2021 ;(13):1594-1594

44. 2021 Chan Fu-Erh,Syu Huei-Min,(Wang Te-Yi,Tang Zheng-Ting,Huang Chih-Ning,Lee Jyh-Fu, Burnouf Thierry, Hu Shang-Hsiu, Chen Po-Chun, Huang Wei-Chen. Iridium Oxide Nanoparticle–Protein Corona Neural Interfaces with Enhanced Electroactivity and Bioactivity Enable Electrically Manipulatable Physical and Chemical Neuronal Activation . Advanced Materials Interfaces .2021 ;(8)

45. 2021 Lassina Barro,Liling Delila,Ouada Nebie,Yu-Wen Wu ,Folke Knutson,Naoto Watanabe, Masayasu Takahara, Thierry Burnouf. Removal of minute virus of mice-mock virus particles by nanofiltration of culture growth medium supplemented with 10% human platelet lysate . Cytotherapy .2021 ;(5):902-907

46. 2021 Josephine H Cheng,Yu-Wen Wu ,Chen-Yun Wang ,Sharon S Wu , Cheum L Hong,Karen W Chan, Leo X Liao, Xisheng Cao, Bin Wang, Thierry Burnouf. Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity . Blood Transfusion (Italy) .2021

47. 2021 Arwa Z Al-Riyami ,Thierry Burnouf,Mark Yazer,Darrell Triulzi,Levent Tufan Kumaş,Levent Sağdur, Nil Banu Pelit, Renée Bazin,... Nancy Dunbar, ISBT Convalescent Plasma Group. International Forum on the collection and use of COVID-19 convalescent plasma: protocols, challenges and lessons learned: Summary . Vox Sanguinis .2021

48. 2021 Arwa Z Al-Riyami,Thierry Burnouf,Mark Yazer,Darrell Triulzi,Levent Tufan Kumaş,Levent Sağdur, Nil Banu Pelit,...Nancy Dunbar. International Forum on the collection and use of COVID-19 convalescent plasma: Responses . Vox Sanguinis .2021

49. 2021 Nebie O,Carvalho K,Barro L,Delila L,Faivre E,Renn TY, Chou ML, Wu YW, Niem-Redene A, Chou SY, Buée L, Hu CH, Peng CW, Devos D, Blum D, Burnouf T. Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment . Brain .2021

50. 2021 Delila L,Wu Y-W,Nebie O,Widyaningrum R,Chou M-L,Devos D, Burnouf T. Extensive characterization of the composition and functional activities of five preparations of human platelet lysates for dedicated clinical uses . Platelets .2021 ;(32(2)):259-272

51. 2020 Lee H-L,Chiou J-F,Lu L-S,Shen C-N,Hsu H-L,Ting L-L, Wang P-W, Burnouf T, Chen Y-J. In vitro expansion and drug sensitivity profiling of circulating tumor cells from patients with extensive-stage small cell lung cancer . Cancers .2020

52. 2020 Jancy Johnson,Yu-Wen Wu,Chantelle Blyth,Gregor Lichtfuss,Hadi Goubran,Thierry Burnouf. Prospective Therapeutic Applications of Platelet Extracellular Vesicles . Trends in Biotechnology .2020

53. 2020 Epstein J,Smid MW,Wendel S,Somuah D,Burnouf T. Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections . Npj Vaccines .2020 ;(5)

54. 2020 Barro L,Burnouf P-A,Chou M-L,Nebie O,Wu Y-W,Chen M-S, Radosevic M, Knutson F, Burnouf T. Human platelet lysates for human cell propagation . Platelets .2020

55. 2020 Schallmoser K, Henschler R,Gabriel C, Koh MBC,Burnouf T*. Production and quality Requirements of human platelet lysate: A Position Statement from the working party on cellular therapies of the International Society of Blood Transfusion . Trends in Biotechnology .2020 ;(38):13-23

56. 2020 Wu YW,Huang CC,Changou CA,Lu LS,Goubran H,Burnouf T. Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop . Journal Biomedical Science .2020 ;(27):1-16

57. 2020 Smid WM,Burnouf T,Epstein J,Kamel H　,Sibinga CS,Somuah D,Stramer SL, Wendel S. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma in low– and middle– income countries. . Africa Sanguine .2020

58. 2020 Epstein J,Smid M,Wendel S,Somuah D,Burnouf T*. Use of COVID‐19 convalescent plasma in low‐ and middle‐income countries: a call for ethical principles and the assurance of quality and safety . Vox Sanguinis .2020

59. 2020 Barro L,Nebie O,Chen M-S,Wu YW,Koh MBC,Knutson F, Watanabe N, Takahara M, Burnouf T. Nanofiltration of growth media supplemented with human platelet lysates for pathogen-safe xeno-free expansion of mesenchymal stromal cells. . Cytotherapy .2020 ;(22):458-472

60. 2020 Bloch EM,Goel R,Wendel S,Burnouf T,Al-Riyami AZ,DeAngelis V, Dumont LJ, Land K, Lee CK, Oreh A, Patidar G, Spitalnik SL, Hindawi S, Van den Berg K, Tiberghien P, Vrielink, H, Young P, Devine D, So-Osman C., and the ISBT Convalescent Plasma Working Group. Guidance for the Procurement of COVID‐19 Convalescent Plasma: Differences between High and Low‐Middle Income Countries. . Vox Sanguinis .2020

61. 2020 Agrahari V,Agrahari V,Chou ML,Chew CH,Noll J, Burnouf T*. Intelligent Micro-/Nanorobots as Drug and Cell Carrier Devices for Biomedical Therapeutic Advancement: Promising Development Opportunities and Translational Challenges . Biomaterials .2020

62. 2020 Jay Epstein,Thierry Burnouf. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma . Vox Sanguinis .2020 ;(115):485-487

63. 2020 Epstein, Jay,Burnouf, Thierry. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. . Vox Sanguinis .2020 ;(115):485-487

64. 2020 Sung TC,Li HF,Higuchi A,Kumar S,Lin QD,Wu YW, Burnouf T, Nasu M, Umezawa A, Lee KF, Wang HC, Chang Y, Hsu ST. Effect of cell culture biomaterials for completely xeno-free generation of human induced pluripotent stem cells. . Biomaterials .2020 ;(230)

65. 2020 Burnouf T*,Epstein J,Faber JC. Recovered plasma for fractionation: call for quality standards to end wastage . Vox Sanguinis .2020 ;(115):213-214

66. 2020 Sabry W,Elemary M,Burnouf T,Seghatchian J,Goubran H. Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy . Transfusion and Apheresis Science .2020 ;(59)

67. 2020 Smid WM,Burnouf T,Epstein J,Kamel H,Sibinga CS,Somuah D,Stramer SL, Wendel S. Eléments à prendre en compte dans la preparation et la transfusion du plasma de personnes guéries du COVID-19 dans les pays à faibles ou moyens revenus. . Africa Sanguine .2020

68. 2019 Ming-Sheng Chen,Tsung-Jen Wang,Hsiu-Chen Lin,Thierry Burnouf. Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cells . New Biotechnology .2019

69. 2019 Vivek Agrahari,Vibhuti Agrahari,Pierre-Alain Burnouf,Chew Chew,Thierry Burnouf. Extracellular microvesicles as new industrial therapeutic frontiers . Trends in Biotechnology .2019

70. 2019 Inouye M,Burnouf T. The role of nanofiltration in the pathogen safety of biologicals: an update. . Current nanoscience .2019

71. 2019 Henschler R,Gabriel C,Schallmoser K,Burnouf T,Koh M. Human Platelet Lysate: Current Standards and Future Developments. . Tranfusion .2019

72. 2019 Obeid S,Sung PS,Le Roy B,Chou ML,Hsieh SL,Caille CE, Burnouf T, Boireau W. NanoBioAnalytical characterization of extracellular vesicles in 75-nm nanofiltered human plasma for transfusion: A tool to improve transfusion safety . Nanomedicine .2019 ;(20)

73. 2019 Barro L,Su YT,Nebie O,Wu YW,Huang YH,Mickey BC Koh ,Knutson F, Burnouf T. A double-virally-inactivated (Intercept–solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells . Transfusion .2019

74. 2019 Hadi Goubran,Mariam Goubran,Jerard Seghatchian,Thierry Burnouf. New monoclonal/bi-specific antibodies: Reshaping transfusion medicine beyond replacement . Transfusion and Apheresis Science .2019 ;(58):208-211

75. 2019 Thierry Burnouf,Jean-Claude Faber,Mirjana Radosevic, Hadi Goubran, Jerard Seghatchian. Plasma fractionation in countries with limited infrastructure and low-/medium income: how to move forward? . Transfusion and Apheresis Science .2019

76. 2019 Agrahari V,Burnouf PA,Burnouf T,Agrahari V. Nanoformulation properties, characterization, and behavior in complex biological matrices: challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential. . Advanced Drug Delivery Reviews .2019

77. 2019 Flore Gouel,Anne-Sophie Rolland,Jean-Christophe Devedjian,Thierry Burnouf,David Devos. Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates. . Frontiers in Neurology .2019

78. 2019 Jean‐Claude Faber, Jay Epstein,Thierry Burnouf. Improving haemophilia therapy in developing countries: virus-safe cryoprecipitate. . Vox Sanguinis .2019

79. 2019 Burnouf T,Chen CH,Tan SJ,Tseng CL,Lu KY,Chang LH, Nyambat B, Huang SC, Jheng PR, Aditya RN, Mi FL, Chuang ER. A bioinspired hyperthermic macrophage-based polypyrrole-polyethylenimine (Ppy-PEI) nanocomplex carrier to prevent and disrupt thrombotic fibrin clots. . Acta Biomaterialia .2019 ;(96):468-479

80. 2019 Burnouf T. Blood products: unmet needs for essential blood products . Lancet Haematology .2019

81. 2019 Gao Y,Ku N-J,Sunb T-C,Higuchi A,Hung C-S,Lee H H-C, Ling Q-D, Cheng N-C, Umezawa A, Barro L, Burnouf T, Ye Q, Chen H.. Effect of human platelet lysate on the differentiation ability of human adipose-derived stem cells cultured on ECM-coated surfaces. . Journal of Materials Chemistry C .2019

82. 2019 Burnouf T,Agrahari V,Agrahari V. Extracellular vesicles as nanomedicines: hopes and hurdles in clinical translation. . The International Journal of Nanomedicine .2019

83. 2019 Burnouf T,Barro L,Nebie O,Wu Y-W,Goubran H,Knutson F, Segatchian J. Virus safety of human platelet lysate for cell therapy and regenerative medicine: moving forward yes, but without forgetting the past. . Transfusion and Apheresis Science .2019

84. 2019 Burnouf T,Epstein J,Faber J-C. Recovered plasma: Call for quality standards to end wastage. . Vox Sanguinis .2019

85. 2019 Nebie O,Devos D,Vingtdeux V,Barro L,Devedjian JC,Jonneaux A, Chou ML, Bordet R, Buée L, Knutson F, Blum D, Burnouf T. The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. . Journal of Biomedical Science .2019 ;(26)

86. 2019 Thierry Burnouf. Blood products: unmet needs for essential medicines . Lancet Haematol .2019

87. 2018 Mantosh Kumar Satapathy,Batzaya Nyambat,Chih-Wei Chiang, Chih-Hwa Chen,Pei-Chun Wong,Po-Hsien Ho. A gelatin hydrogel-containing nano-organic PEI–Ppy with a photothermal responsive effect for tissue engineering applications . Molecules .2018

88. 2018 Renn TY,Huang YK,Feng SW,Wang HW,Lee WF,Lin CT, Burnouf T, Chen LY, Kao PF, Chang HM. Prophylactic supplement with melatonin successfully suppresses the pathogenesis of periodontitis through normalizing RANKL/OPG ratio and depressing the TLR4/MyD88 signaling pathway . Journal of Pineal Research .2018 ;(64):1-21

89. 2018 Victor J. Drew,Ching-Li Tseng,Jerard Seghatchian,Thierry Burnouf. Reflections on dry eye syndrome treatment: Therapeutic role of blood products . Frontiers in Medicine .2018

90. 2018 Sut C,Hamzet-Cognasse H,Arthaud CA,Evraud MA,Chettab K,Dumontet C, Laradi S, Burnouf T, Garraud O, Cognasse F. Platelet concentrate supernatants alter endothelial cell mRNA and protein expression patterns as a function of storage length . Transfusion .2018

91. 2018 Barro L,Drew V,Poda GD,Tagny CT,El-Ekiaby M,Owusu-Ofori S, Burnouf T. Blood transfusion in sub-Saharan Africa: filling the gap to fulfill local needs and respond to present and future challenges . Vox Sanguinis (in press) .2018

92. 2018 Huang CN,Tang ZT,Chan FE,Burnouf T,Huang WC,Chen PC. Fabrication of co-electrodeposition of plasma proteins/iridium oxide hybrid films . Ceramics International .2018 ;(44):S117-S120

93. 2018 Thierry Burnouf. Principles of haemophilia care: The Asia- Pacific perspective . Haemophilia .2018

94. 2018 Paul Harrison,J. Alsousou, Liverpool, UK; I. Andia, Barakaldo, Spain; T. Burnouf, Taipei City, Taiwan; D. Dohan Ehrenfest, Gwangju, South Korea; P. Everts, Fort Myers, USA; H. Langer, Tu€bingen, Germany; J. Magalon, Marseille, France; R. Marck, Amsterdam, the Netherlands; P. Gre- sele, Perugia, Italy.. The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTH . Journal of Thrombosis and Haemostasis .2018 ;(16):1895-1900

95. 2018 Thierry Burnouf. What can be learned in the snake antivenom field from the developments in human plasma derived products? . Toxicon .2018 ;(146):77-86

96. 2018 D. Strunk,M. Lozano,D. C. Marks,Y. S. Loh,G. Gstraunthaler,H. Schennach, E. Rohde, S. Laner-Plamberger, M. Oller, J. Nystedt, R. Lotfi, M. Rojewski, H. Schrezenmeier, K. Bieback, R. Schafer, T. Bakchoul, M. Waidmann, S. M. Jonsdottir-Buch, H. Montazeri, O. E. Sigurjonsson, P. Iudicone, D. Fioravanti, L. Pierelli, M. Introna, C. Capelli, A. Falanga, M. Takanashi, O. Lopez-Villar, T. Burnouf, J. A. Reems, J. Pierce, A. M. Preslar, K. Schallmoser. International Forum on GMP-grade human platelet lysate for cell propagation . Vox Sanguinis .2018 ;(113)

97. 2018 Lassina Barro,Victor J. Drew,Ghislain G. Poda,Claude T. Tagny,Magdy El-Ekiaby,Shirley Owusu-Ofori, Thierry Burnouf. Blood transfusion in sub-Saharan Africa: understanding the missing gap and responding to present and future challenges . Vox Sanguinis .2018 ;(113):726-736

98. 2018 Jean-Claude Faber,Thierry Burnouf. Bitter progress in the treatment of haemophilia A in low-income countries . Lancet Haematology .2018 ;(5)

99. 2018 Thierry Burnouf,Pierre-Alain Burnouf,Yu-Wen Wu,Er-Yuan Chuang,Long-Sheng Lu,Hadi Goubran. Circulatory-cell-mediated nanotherapeutic approaches in disease targeting . Drug Discovery Today .2018 ;(23):934-943

100. 2018 D. Strunk,M. Lozano,D. C. Marks,Y. S. Loh,G. Gstraunthaler,H. Schennach, E. Rohde, S. Laner-Plamberger, M. Oller, J. Nystedt, R. Lotfi, M. Rojewski, H. Schrezenmeier, K. Bieback, R. Schafer, T. Bakchoul, M. Waidmann, S. M. JonsdottirBuch, H. Montazeri, O. E. Sigurjonsson, P. Iudicone, D. Fioravanti, L. Pierelli, M. Introna, C. Capelli, A. Falanga, M. Takanashi, O. Lόpez-Villar, T. Burnouf, J. A. Reems, J. Pierce, A. M. Preslar, K. Schallmoser. International Forum on GMP‐grade human platelet lysate for cell propagation: summary . Vox Sanguinis .2018 ;(113):80-87

101. 2018 Thierry Burnouf. Multifaceted regenerative lives of‘expired’platelets . Vox Sanguinis .2018 ;(13):323-330

102. 2018 Thierry Burnouf. Preface: Annals of Blood Special issue on plasma fractionation. . Annals of Blood .2018

103. 2018 Thierry Burnouf,Magdy El Ekiaby,Hadi Goubran,Mirjana Radosevich,Ahmed El Ekiaby. Role of the mini-pool cryoprecipitate technology for cost-saving and guarantee of local Factor VIII, Von Willebrand Factor and Fibrinogen product supply: Egypt experience. . Annals of Blood .2018

104. 2018 Thierry Burnouf. An overview of plasma fractionation . Annals of Blood .2018

105. 2017 Kim MJ,Burnouf T. The Current Global Status and Production Trends of Plasma Fractionation . Korean J Blood Transfus .2017

106. 2017 Gouel F,Do Van B,Chou ML,Jonneaux A,Moreau C,Bordet R, Burnouf T, Devedjian JC, Devos D. The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways. . J Tissue Eng Regen Med .2017 ;(11):3236-3240

107. 2017 Wang TJ,Chen MS,Chou ML,Lin HC,Seghatchian J,Burnouf, T. Comparison of three human platelet lysates used as supplements for in vitro expansion of corneal endothelium cells . Transfus Apher Sci .2017 ;(56):769-773

108. 2017 Goubran H,Seghatchian J,Prokopchuk-Gauk O,Radosevic J,Sabry W,Iqbal N, Burnouf T. Reflections on multiple strategies to reduce transfusion in cancer patients: A joint narrative. . Transfus Apher Sci .2017 ;(56)

109. 2017 Strunk D,Lozano, M,Marks, DC,Loh YS,Gstraunthaler G,Schennach H, Rohde E, Laner-Plamberger S, Oller M,  Nystedt J, Lotfi R, Rojewski M, Schrezenmeier H, Bieback K, Schafer R, Bakchoul T Waidmann M, Jonsdottir-Buch SM, Montazeri, H, Sigurjonsson OE, Iudicone, P, Fioravanti, D, Pierelli, L, Introna, M, Capelli, C, Falanga, A, Takanashi, M, Lόpez-Villar O, Burnouf T, Reems, JA, Pierce, J, Preslar, AM, Schallmoser, K. International Forum on GMP-grade human platelet lysate for cell propagation: a summary . Vox Sanguinis .2017

110. 2017 Goubran H,Seghatchian J,Radosevic J,Ragab G,Burnouf T. The microbiome and transfusion in cancer patients . Transfus Apher Sci .2017 ;(56):330-335

111. 2017 Goubran H,Sheridan D,Radosevic J,Burnouf T,Seghatchian J. Transfusion-related immunomodulation and cancer . Transfus Apher Sci .2017 ;(56):336-340

112. 2017 Burnouf T,Elemary M,Radosevic J,Seghatchian J,Goubran H. Platelet transfusion in thrombocytopenic cancer patients: Sometimes justified but likely insidious . Transfus Apher Sci .2017 ;(56):305-309

113. 2017 Iqbal N,Haider K,Sundaram V,Radosevic J,Burnouf T,Seghatchian J, Goubran H. Red blood cell transfusion and outcome in cancer . Transfus Apher Sci .2017 ;(56):287-290

114. 2017 Drew V,Barro L,Seghatchian J,Burnouf T. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prosoects for developing countries . Blood Transfusion (Italy) .2017 ;(15):1-11

115. 2017 Sut C,Tariket S,Chou ML,Garraud O,Laradi S,Hamzeh-Cognasse H, Seghatchian J, Burnouf T, Cognasse F. Duration of red blood cell storage and inflammatory marker generation. . Blood Transfus .2017 ;(15):145-152

116. 2017 Burnouf T,Dye JM,Abayomi A. Convalescent Plasma and the Dose of Ebola Virus Antibodies . New England Journal of Medicine .2017 ;(376):1296-1297

117. 2017 Lee KT,Lu YJ,Mi FL,Burnouf T,Wei YT,Chiu Shao-Chieh, Chaung EY, Lu SY. Catalase-Modulated Heterogeneous Fenton Reaction for Selective Cancer Cell Eradication: SnFe2O4 Nanocrystals as an Effective Reagent for Treating Lung Cancer Cells . ACS Appl. Mater. & Interfaces .2017

118. 2017 Chou ML,Wu JW,Gouel F,Jonneaux A,Timmerman K,Renn TY, Laloux C, Chang HM, Lin LT, Devedjian JC, Devos D, Burnouf T. Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease . Biomaterials .2017 ;(142):77-89

119. 2017 Mi FL,Burnouf T*,Lu SY,Lu YJ,Lu KY,Ho YC, Kuo CY, Chuang EY. Self-Targeting, Immune Transparent Plasma Protein Coated Nanocomplex for Noninvasive Photothermal Anticancer Therapy. . Adv Healthcare Mat .2017 ;(6):1700181-1700181

120. 2016 Burnouf T. Plasma for fractionation: looking at its safety from a comprehensive angle. . Transfusion .2016 ;(56):2900-2901

121. 2016 Seghatchian J,Espinosa A,Burnouf T. Commentary on technical specifications and safety requirements of serum eye drops: Keeping a close eye on the content in cytokines. . Transfusion & Apheresis Science .2016

122. 2016 Seghatchian J,Espinosa A,Burnouf T. Quality, safety, and sustained therapeutic efficacy of blood-derived serum eye drops to treat dry eye syndrome: R&D road map for future progress. . Transfusion & Apheresis Science .2016

123. 2016 T. Burnouf,J. M. Dye,J. Ambe,A. Abayomi. Convalescent Ebola plasma: assessing neutralizing antibodies at the right stage . Vox Sanguinis .2016

124. 2016 T. Burnouf. Current status and new developments in the production of plasma derivatives . vox sanguinis .2016 ;(11):18-25

125. 2016 Thierry Burnouf, Ph.,Brian Conton,John M. Dye, Ph.D.. Convalescent Plasma for Ebola Virus Disease . New England Journal of Medicine .2016 ;(374):2499

126. 2016 Chueh-Yao Chung,Ching-Hsuan Liu,Thierry Burnouf,Guey-Horng Wang,Shun-Pang Chang,Alagie Jassey, Chen-Jei Tai, Cheng-Jeng Tai, Ching-Jang Huang,Christopher D. Richardson, Ming-Hong. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry . Antiviral Research .2016

127. 2016 Yu-Wen Wu,Hadi Goubran,Jerard Seghatchian,Thierry Burnouf. Smart blood cells and microvesicle-based Trojan Horse drug delivery: Merging blood transfusion and biomedical engineering expertise in the field of nanomedicine . Transfusion and Apheresis Science .2016

128. 2016 Hadi A. Goubran,Mohamed Elemary,Miryana Radosevich,Jerard Seghatchian,Magdy El-Ekiaby,Thierry Burnouf. Impact of Transfusion on Cancer Growth and Outcome . Cancer Growth and Metastasis .2016

129. 2016 Ching-Li Tseng,Zhi-Yu Chen,Ting-Yi Renn,Shun-Hung Hsiao,Thierry Burnouf. Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome . PLoS One .2016

130. 2016 T . BURNOUF,P.F.W. STRENGERS. Risks of inhibitors from recombinant factor VIII: a quarter of a century to reach the conclusion . Journal of Thrombosis and Haemostasis .2016 ;(14):2073-2074

131. 2016 Jerard Seghatchian,Aurora Espinosa,Thierry Burnouf. Quality, safety and sustained therapeutic efficacy of blood derived serum eye drops to treat dry eye syndrome: R&D road map for future progress . Transfusion and Apheresis Science .2016

132. 2016 Yao-Ting Hsieh,Lori Mullin,Patricia Greenhalgh,Michael Cunningham,Elizabeth Goodrich,Jessica Shea,Eric Youssef, Thierry Burnouf. Single-use technology for solvent/detergent virus inactivation of industrial plasma products . TRANSFUSION .2016

133. 2016 Ying-Jan Weng,Anne Husebekk,Björn Skogen,Mette Kjaer,Liang-Tzung Lin,Thierry Burnouf. Anti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia . PLOS ONE .2016

134. 2016 Kao YC,Bailey A,Samminger B,Tanimoto J,Burnouf T. Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion . Cytotherapy .2016 ;(18):911-924

135. 2016 Burnouf T,Strunk D,Koh M,Schallmoser K. Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? . Biomaterials .2016 ;(76):371-387

136. 2016 Chou ML,Burnouf T. Current methods to manufacture human platelet lysates (HPLs) for cell therapy and tissue engineering; possible trends in product safety and standardisation . Vox Sanguinis .2016 ;(12):168-175

137. 2016 Thierry Burnouf,Brian Conton,John M. Dye. To the editor . New England Journal of Medicine .2016

138. 2016 ‪Ming Li Chou,Thierry Burnouf. Current methods to manufacture human platelet lysates (HPLs) for cell therapy and tissue engineering: possible trends in product safety and standardization . Vox Sanguinis .2016 ;(12):168-175

139. 2016 M.L. Chou, T. Burnouf. Current methods to manufacture human platelet lysates (HPLs) for cell therapy and tissue engineering; possible trends in product safety and standardisation. . Vox Sanguinis .2016

140. 2015 Hadi Goubran,Waleed Sabry,Rami Kotb,Jerard Seghatchian,Thierry Burnouf. Platelet microparticles and cancer: An intimate cross-talk . Transfusion and Apheresis Science .2015

141. 2015 Shih DTB,Burnouf T. Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion . New Biotechnology .2015 ;(32):199-211

142. 2015 Lin HC,Chang HW,Hsiao SH,Chou ML,Seghatchian J,Burnouf T. Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro. . Transfus Apher Sci. .2015

143. 2015 Burnouf T,Chou ML,Goubran H,Cognasse F,Garraud O,Seghatchian J. An overview of the role of microparticles/microvesicles in blood components: Are they clinically beneficial or harmful? . Transfusion and Apheresis Science .2015 ;(53):137-145

144. 2015 Cognasse F,Hamzeh-Cognasse H,Laradi S,Chou ML,Seghatchian J,Burnouf T, Boulanger C, Garraud O, Amabile N.. The role of microparticles in inflammation and transfusion: A concise review. . Transfus Apher Sci. .2015 ;(53):159-167

145. 2015 El-Ekiaby M,Vargas M,Sayed M,Gorgy G,Goubran H,Radosevic M, Burnouf T. Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries. . PLoS Negl Trop Dis. .2015

146. 2015 Chou ML,Burnouf T,Chang SP,Hung TC,Lin CC,Richardson CD, Lin LT. TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus. . PLOS ONE .2015

147. 2015 Chou ML,Bailey A,Avory T,Tanimoto J,Burnouf T. Removal of transmissible spongiform encephalopathy prion from large volumes of cell culture media supplemented with fetal bovine serum by using hollow fiber anion-exchange membrane chromatography. . .2015 ;(1):1-1

148. 2015 Vargas M,Segura A,Wu YW,Herrera M,CHou ML,Villalta M, LeonG, Burnouf T. Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity. . Vox Sanguninis .2015 ;(108):169-177

149. 2015 Goubran HA,Burnouf T,Stawik J,Segatchian J. Platelet microparticle: A sensitive physiological “fine tuning” balancing factor in health and disease . Transfusion & Apheresis Science .2015 ;(52):12-18

150. 2015 T.-Y. Renn,Y.-H. Kao,C._C. Wang,T. Burnouf. Anti-inflammatory effects of platelet biomaterials in a macrophage cellular model . Vox Sangunis .2015 ;(109):138-147

151. 2015 Chou ML,Lin LT,Devos D,Burnouf T. Nanofiltration to remove microparticles and decrease the thrombogenicity of plasma: in vitro assessment. . Transfusion .2015 ;(55):2433-2444

152. 2015 Tseng CL,Seghatchain J,Burnouf T. Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: Seeing is believing. . Transfusion & Apheresis Science .2015 ;(53):95-98

153. 2015 Hsiu-Chen Lin,Hui-Wen Chang,Shun-Hung Hsiao,Ming-Li Chou,Jeard Seghatchian,Thierry Burnouf. Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro . Transfusion & Apheresis Science .2015

154. 2015 Guttierez J,Burnouf T,Harrison RA,Calvete JJ,Brown N,Jensen SD, Warrell DA, Williams DJ. A Call for Incorporating Social Research in the Global Struggle against Snakebite. . PLOS Neglected Tropical Diseases .2015

155. 2014 Sherif N,Goubran HA,Hassan A,Burnouf T*,,El-Ekiaby M. An approach to outreach patients with Von Willebrand Disease in Egypt by targeting women with heavy menstrual bleeding and/or bleeding symptoms. . Haemophilia .2014 ;(20):238-243

156. 2014 Wu YW,Champagne J,Toueille M,Gantier R,Burnouf, T. Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG. . Transfusion .2014

157. 2014 Gutierrez JM,Burnouf T,Harrison RA,Calvete JJ,Kuch U,Warrell DA,William DJ. A multi-component strategy to improve the availability of effective and safe antivenom immunoglobulins for treating snakebite envenoming. . Bulletin of the World Health Organization .2014 ;(0):0-0

158. 2014 Burnouf T,Seghatchian J,Goubran HA. Multifaceted regenerative lives of expired platelets in the second decade of the 21st century. . Transfusion & Apheresis Science. .2014

159. 2014 Germishuizen WA,Gyure DC,Stubbings D,Burnouf T*. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products . Biologicals .2014

160. 2014 Burnouf T,Goubran HA,Chou ML,Devos, D,Radosevic M.. Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine. . Blood Rev .2014 ;(4):155-66

161. 2014 Goubran HA,Stakiw J,Radosevich M,Burnouf T. Platelets effects on tumor growth . Seminars in Oncology .2014 ;(41):359-69

162. 2014 Goubran HA*,Kotb R,Stakiw J,Emara M,Burnouf T. Regulation of tumor growth and metastasis: the role of tumor microenvironment. . Cancer Growth Metastasis. .2014 ;(7):9-18

163. 2014 Goubran HA,Stakiw J,Radosevich M,Burnouf T. Platelet-cancer interactions. . Seminars in Thrombosis and Hemostasis .2014 ;(40):296-305

164. 2014 Burnouf T,Emmanuel J,Mbanya D,El-Ekiaby M,Murphy W,Field S. Ebola: a call for blood transfusion strategy in sub-Saharan Africa . Lancet .2014 ;(384):1347-1348

165. 2014 Chou ML,Burnouf T,Wang TJ. Ex vivo Expansion of Bovine Corneal Endothelial Cells in Xeno-Free Medium Supplemented with Platelet Releasate . PLOS ONE .2014 ;(9)

166. 2014 Thierry Burnouf a,Jerard Seghatchian. “Go no Go” in plasma fractionation in the world’s emerging economies: Still a question asked 70 years after the COHN process was developed! . Transfusion and Apheresis Science .2014 ;(51):113-119

167. 2014 Thierry Burnouf,Jerard Seghatchian. Ebola virus convalescent blood products: Where we are now and where we may need to go . Transfusion and Apheresis Science .2014 ;(51):120-125

168. 2014 Thierry Burnouf,Hadi Alphonse Goubr,Jerard Seghatchian. Multifaceted regenerative lives of expired platelets in the second decade of the 21st century . Transfusion and Apheresis Science .2014 ;(51):107-112

169. 2014 Thierry Burnouf. New approaches for manufacturing plasma derivatives. . ISBT Science Series .2014

170. 2013 Burnouf T,Goubran H,Chen TM,Ou KL,El-Ekiaby M,Radosevic M. Blood-derived biomaterials and platelet growth factors in regenerative medicine. . Blood Reviews .2013 ;(2):77-89

171. 2013 Lee YL,Lee LW,Su CY,Hsiao G,Yang YY,Leu SJ, Shieh YH, Burnouf T. Virally inactivated human platelet concentrate lysate induces regulatory T cells and immunosuppressive effect in a murine asthma model . Transfusion .2013 ;(53):1918-1928

172. 2013 Goubran HA,Burnouf T,Radosevic M,El-Ekiaby M. The platelet-cancer loop . European Journal of Internal Medicine .2013 ;(24):393-400

173. 2013 Tzeng YS,Deng SC,Wang CH,Tsai JC,Chen TM,Burnouf T. Treatment of nonhealing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a case series . BioMed Research International .2013

174. 2013 Pai SC,Burnouf T,Chen JW,Lin LI. Human Platelet Antigen Alleles in 998 Taiwanese Blood donors determined by sequence-specific primer polymerase chain reaction. . BioMed Research International .2013

175. 2013 Burnouf T,Chou ML,Cheng LH,Li ZR,Wu YW,El-Ekiaby M, Tsai KH. Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate . Vox Sanguinis .2013 ;(104):1-6

176. 2013 Chen TM,Tzeng YS,Tsai JC,Burnouf T. Single-donor allogeneic platelet fibrin glue and osteoconductive scaffold in orbital floor fracture reconstruction . annals of plastic surgery .2013 ;(70):370-374

177. 2013 Burnouf T,Chou ML,Wu YW,Su CY,Lee LW. Antimicrobial activity of platelet (PLT)-poor plasma, PLT-rich plasma, PLT gel, and solvent/detergent-treated PLT lysate biomaterials against wound bacteria . transfusion .2013 ;(53):138-146

178. 2012 Vargas M,Segura A,Herrera M,Villalta M,Angulo Y,Gutiérrez JM, León G, Burnouf T. Purification of IgG and albumin from human plasma by aqueous two phase system fractionation . Biotechnol. Prog .2012 ;(28):1005-1011

179. 2012 Solano S,Segura Á,León G,Gutiérrez JM,Burnouf T. Low pH formulation of whole IgG antivenom: Impact on quality, safety, neutralizing potency and viral inactivation . Biologicals .2012 ;(40):129-133

180. 2012 H.A. Goubran,T. Burnouf. Platelets, coagulation and cancer: Multifaceted Interactions . American Medical Journal .2012 ;(3):130-140

181. 2012 Burnouf T,Kuo YP,Blum D,Burnouf S,Su CY. Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor . TRANSFUSION .2012 ;(52):1721-1728

182. 2012 Burnouf T,Lee CY,Luo CW,Kuo YP,Chou ML,Wu YW, Tseng YH, Su CY. Human blood-derived fibrin releasates: Composition and use for the culture . Biologicals .2012 ;(40):21-30

183. 2012 Chou ML,Wu YW,Su CY,Lee LW,Burnouf T. Impact of solvent/detergent treatment of plasma on transfusion-relevant bacteria . Vox Sanguinis .2012 ;(102):277-284

184. 2011 Burnouf T. Recombinant plasma proteins . Vox Sanguinis .2011 ;(100):68-83

185. 2011 Shih DT,Chen JC,Chen WY,Kuo YP,Su CY,Burnouf T. Expansion of adipose tissue mesenchymal stromal progenitors in serum-free medium supplemented with virally-inactivated allogeneic human platelet lysate. . transfusion .2011 ;(51):770-778

186. 2011 Gutiérrez JM,León G,Burnouf T. Antivenoms for the treatment of snakebite envenomings: The road ahead . Biologicals .2011 ;(39):129-142

187. 2011 Burnouf T,Radosevic M,El-Ekiaby M,Goubran H. Pathogen Reduction Technique for fresh frozen plasma,cryoprecipitate and plasma fractions minipools prepared in disposable processing bag systems . transfusion .2011 ;(51):446-447

188. 2011 El-Ekiaby M,Goubran HA,Radosevich M,Abd-Allah A,El-Ekiaby A,Burnouf T. Pharmacokinetics study of minipool solvent/detergent-filtered cryoprecipitate factor VIII . Haemophilia .2011 ;(17):e884-e888

189. 2011 Burnouf T,Chang CW,Kuo YP,Wu YW,Tseng YH,Su CY. A chromatographically purified human TGF-β1 fraction from virally-inactivated platelet lysates . Vox Sanguinis .2011 ;(101):215-220

190. 2010 Burnouf PA,Juan PK,Su CY,Kuo YP,Chou ML,Su CH, Tseng YH, Lin CT, Burnouf T. A novel virally-inactivated human platelet lysate preparation rich in TGF-β, EGF and IGF, depleted of PDGF and VEGF . Biotechnology and Applied Biochemistry .2010 ;(56):151-160

191. 2010 Burnouf T,Kuo YP,Huang CT,Tseng YH,Lin CT,Su CY. A virally inactivated platelet-derived growth factor/vascular endothelial growth factor concentrate fractionated from human platelets . transfusion .2010 ;(50):1702-1711

192. 2010 Chen TM,Tsai JC,Burnouf T. A Novel Technique Combining Platelet Gel, Skin Graft, and Fibrin Glue for Healing Recalcitrant Lower Extremity Ulcers . Dermatologic surgery .2010 ;(36):453-460

193. 2010 Thierry Burnouf,Allan Lihme,Marie BendixHansen,Inga VaarstAndersen. A novel core fractionation process of human plasma by expanded bed adsorption chromatography . Analytical Biochemistry .2010

194. 2010 Thierry Burnouf,Ya PoKuo,Yueh-LunLee,Yu HongTseng,Ching-HuaSu,Chen YaoSu. Influence of ethanol on the release of growth factors in human blood-derived platelet gels . Biologicals .2010

195. 2010 H. Goubran , M. El‐Ekiaby,M. Radosevich , M. A. Sayed, J. Goudemand , C. Caron,D. Blum , S. Burnouf, L. De Melo , N. El‐Sharkawy,V. Soulié , J. Adam , Thierry Burnouf. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system . Transfusion Medicine .2010

196. 2009 Thierry Burnouf,M. Radosevich. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. . Vox Sanguinis .2009

197. 2009 Thierry Burnouf,ÁlvaroSegura,GuillermoLeón,Chen-YaoSu,osé-MaríaGutiérrez. Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom . Biologicals .2009

198. 2009 Thierry Burnouf,C.‐Y. Su, Y. P. Kuo, Y. C. Lin,C.‐T. Huang, Y. H. Tseng. A virally inactivated functional growth factor preparation from human platelet concentrates . Vox Sanguinis .2009

199. 2009 Thierry Burnouf,Chen YaoSu,Ya PoKuo,Yu HongTseng,Ching-HuaSu. In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF . Oral Surgery .2009

200. 2009 Thierry Burnouf,AlbertFarrugia,TheoEvers,Pierre-FrancoisFalcou,LuizAmorim,SylviaThomas. Plasma fractionation issues . Biologicals .2009

201. 2009 Thierry Burnouf,M. El‐Ekiaby, M. Radosevich,H. Goubran, M. El Sayed. New methods of plasma fractionation – a presentation of the ‘mini‐pool’ fractionation procedure developed in Egypt . ISBT Science Series .2009

202. 2009 T. Burnouf,C.‐Y. Su,M. Radosevich,H. Goubran,M. El‐Ekiaby. Blood-derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue. . ISBT Science Series .2009

203. 2009 Burnouf T,Sayed MA,Radosevich M,El-Ekiaby M. Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR HyperD and C18 sorbents . Analytical Biochemistry .2009 ;(389):69-73

204. 2008 Burnouf T,Tseng YH,Kuo YP,Su CY. Solvent/detergent treatment of platelet concentrates enhances the release of growth factors . transfusion .2008 ;(48):1090-1098

205. 2008 Su CY,Kuo YP,Nieh HL,Tseng YH,Burnouf T. Quantitative assessment of the kinetics of growth factors release from platelet gel . transfusion .2008 ;(48):2414-2420

206. 2008 Thierry Burnouf. Quality of plasma and its fractionation. . ISBT Science Series .2008

207. 2008 Thierry Burnouf,H.A.Goubran,M.Radosevich,M.El-Ekiaby. Inactivation virale par procédé solvant-détergent de minipools de plasma, de cryoprécipité et de surnageant de cryoprécipité dans des dispositifs à usage unique . Transfusion Clinique et Biologique .2008

208. 2008 Thierry Burnouf,C. CARON,M. RADOSEVICH,H. A. GOUBRAN,J. GOUDEMAND,M. EL‐EKIABY. Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems . Haemophilia .2008

209. 2008 Thierry Burnouf. Actualités sur les médicaments dérivés du sang . Hematologie .2008

210. 2008 Thierry Burnouf,Tim Mo Chen,Jui-Che Tsai. Cranioplasty Using Osteoconductive Scaffold and Platelet Glue . The Journal of Trauma: Injury, Infection, and Critical Care. .2008

211. 2007 Thierry Burnouf, H. A. Goubran, M. Radosevich, M. El‐Ekiaby. Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries . ISBT Science Series .2007

212. 2007 Thierry Burnouf,FokkeTerpstra,GeorgeHabib,SalwaSeddik. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms . Biologicals .2007

213. 2007 Thierry Burnouf,Hadi AlphonseGoubran,MiryanaRadosevich,Makram A.Sayed,GeorgeGorgy,MagdyEl-Ekiaby. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma . Biologicals .2007

214. 2007 Thierry Burnouf. Modern Plasma Fractionation . Transfusion Medicine Reviews .2007

215. 2007 José MaríaGutiérrez,HisakoGondo Higashi,FanHui Wen,Thierry Burnouf. Strengthening antivenom production in Central and South American public laboratories: Report of a workshop . Toxicon .2007

216. 2007 Miryana Radosevich, Thierry Burnouf. Biological and biochemical assays to ensure the quality and safety of plasma-derived products: Factor VIII concentrates . Current Pharmaceutical Analysis .2007

217. 2005 T. Burnouf,M. Radosevich,H. A. Goubran,H. Willkommen. Place of nanofiltration for assuring viral safety of biologicals. . Current Nanoscience .2005

技術論文 Technical Report


1. 2013 George Watt,Pacharee Kantipong,Thierry Burnouf,Cecilia Shikuma,Sean Philpott. Natural scrub typhus antibody suppresses HIV CXCR4(X4) viruses . Infectious Disease Reports .2013 ;(5:e8):27-31

書籍 Book


1. 2017 Burnouf T,Liu CH,Lin LT. Strategies to preclude hepatitis C virus entry . Advances in Treatment of Hepatitis C and B .2017

專利 Patent


1. 2006 Sakae Sato,Tetsuo Sato,Thierry Burnouf,Miryana Radosevich,Hadi Alphonse Goubran. Viral reduction method for plasma using a leukocyte-reduction filter and two virus-reduction filters of decreasing pore diameters . patent .2006

2. 2004 Thierry Burnouf. Device for activating human thrombin in vitro . patent .2004

其它 Other


1. 2015 Seghatchian J,Burnouf T. Blood cell-derived microvesicles with potential pathogenic roles in therapeutic blood components and specialized diagnostic tools in diseases . Transfusion & Apheresis Science .2015

研究計畫

計畫名稱
113 利用血小板衍生的CCL5促進神經增生和認知增強：臨床級方法(1/3)
補助單位
國家科學及技術委員會
計畫名稱
113 延攬印尼籍Liling Delila Liling君參與「利用血小板衍生的CCL5促進神經增生和認知增強：臨床級方法」研究計畫案，申請本會補助，業經核定以「博士級研究人員」資格補助(NSTC 113-2811-B-038-018)
補助單位
國家科學及技術委員會
計畫名稱
112 應用生物工程製程純化之血小板分泌蛋白質體生物材料於腦部年輕再生之治療(3/3)
補助單位
國家科學及技術委員會
計畫名稱
112 The potential protective effects of heat-treated platelet pellet lysate on tau hyperphosphorylation.
補助單位
國家科學及技術委員會
計畫名稱
112 Transplantation of Platelet Mitochondria in Cells induced with Parkinson's and Alzheimer's Disease
補助單位
國家科學及技術委員會
計畫名稱
112 應用生物工程製程純化之血小板分泌蛋白質體生物材料於腦部年輕再生之治療(3/3)
補助單位
國家科學及技術委員會
計畫名稱
112 「補助國內研究生出席國際學術會議」申請費用補助案 ( 研究生：國際生醫工程博士學位學程博士班 LE THAO NGOC NHI 君 )
補助單位
國家科學及技術委員會
計畫名稱
112 「補助國內研究生出席國際學術會議」申請費用補助案 ( 研究生：國際生醫工程博士學位學程博士班 Ariunjarga l NyamErdene 君 )
補助單位
國家科學及技術委員會
計畫名稱
112 臺歐盟國合計畫－裝載富含生長因子的胞外囊泡功能化石墨烯水凝膠應用於肌膚再生(3/3)
補助單位
國家科學及技術委員會
計畫名稱
111 應用生物工程製程純化之血小板分泌蛋白質體生物材料於腦部年輕再生之治療(2/3)
補助單位
國家科學及技術委員會
計畫名稱
111 臺歐盟國合計畫－裝載富含生長因子的胞外囊泡功能化石墨烯水凝膠應用於肌膚再生(2/3)
補助單位
國家科學及技術委員會
計畫名稱
110 Intranassal immunotherapy of neurological disorders-prospective translation assessment
補助單位
國家科學及技術委員會
計畫名稱
110 Optimization and fractionation of AventaCell clinical-grade human platelet lysate for translational applications in cell therapy and regenerative medicine
補助單位
AventaCell Biomedical Corp. Ltd
計畫名稱
110 Evaluation of the safety of Planova 20N-nanofiltered human platelet pellet lysate and capacity to stimulate brain neuronal differentiation
補助單位
Asahi Kasei Medical Co., Ltd.
計畫名稱
110 Optimizations of conditions for the nanofiltration in a mini-pool process of plasma-derived immunoglobulin G used for treatment of emerging infections and immunological disorders using Asahi Kasei Medical nanofilters
補助單位
Asahi Kasei Medical Co., Ltd.
計畫名稱
110 應用生物工程製程純化之血小板分泌蛋白質體生物材料於腦部年輕再生之治療(1/3)
補助單位
科技部
計畫名稱
110 貴機構依本部「補助國內研究生出席國際學術會議」申請費用補助案(研究生：生物醫學工程學系碩士班LE THAO NGOC NHI君)，業經核定，請查照辦理
補助單位
科技部
計畫名稱
110 貴機構依本部「補助國內研究生出席國際學術會議」申請費用補助案(研究生：生物醫學工程學系博士班Liling君)，業經核定，請查照辦理。
補助單位
科技部
計畫名稱
110 臺歐盟國合計畫－裝載富含生長因子的胞外囊泡功能化石墨烯水凝膠應用於肌膚再生(1/3)
補助單位
國家科學及技術委員會
計畫名稱
110 血小板奈米粒子作為抗癌藥物之標靶傳輸系統
補助單位
財團法人國家衛生研究院
計畫名稱
109 RESEARCH SERVICE AGREEMENT ON FEASABILITY STUDY OF SCALABLE PROCESSES USING SINGLE-USE EQUIPMENT AND RECYCLABLE CHROMATOGRAPHIC RESINS TO PURIFY IMMUNOGLOBULINS FROM NORMAL, HYPERIMMUNE, AND CONVALESCENT PLASMA
補助單位
台灣默克股份有限公司
計畫名稱
109 Evaluation of Planova 20N-nanofiltration on human platelet pellet lysate proteome and capacity to stimulate brain neurogenesis
補助單位
Asahi Kasei Medical Co., Ltd.
計畫名稱
109 Evaluation and development of conditions for the nanofiltration of selected plasma-derived immunoglobulins used for treatment of emerging infections and immunological disorders using Asahi Kasei Medical nanofilters
補助單位
Asahi Kasei Medical Co., Ltd.
計畫名稱
109 探討新穎性血小板奈米囊泡作為遞送神經生物分子載具於腦部再生之應用(3/3)
補助單位
科技部
計畫名稱
109 生物醫學工程學系博士班研究生Liling Delila君擬於109年12月12日至109年12月16日參加The 36th International Congress of the ISBT 2020
補助單位
科技部
計畫名稱
109 貴校生醫材料暨組織工程研究所碩士班研究生李登耀君擬於110年5月18日至110年5月21日參加國際細胞外囊泡學會，依本部補助國內研究生出席國際學術會議作業要點申請補助費用一案，核定補助如說明，請查照
補助單位
科技部
計畫名稱
109 血小板奈米粒子作為抗癌藥物之標靶傳輸系統
補助單位
財團法人國家衛生研究院
計畫名稱
108 評估血小板神經營養因子調控濤譯蛋白過度磷酸化在創傷性腦損傷神經修復之療效(2/2)
補助單位
科技部
計畫名稱
108 Characterization and isolation of extracellular vesicles obtained from UnicoCell adipose tissue mesenchymal stromal cells conditioned medium
補助單位
向榮生醫科技股份有限公司
計畫名稱
108 Evaluation and development of conditions for the nanofiltration of selected human platelet lysates (HPL) used for cell therapy and regenerative medicine using Asahi Kasei Medical nanofilters – especially concerning virus-like particle removability
補助單位
Asahi Kasei Medical Co., Ltd.
計畫名稱
108 探討新穎性血小板奈米囊泡作為遞送神經生物分子載具於腦部再生之應用(2/3)
補助單位
科技部
計畫名稱
108 血小板奈米粒子作為抗癌藥物之標靶傳輸系統
補助單位
財團法人國家衛生研究院
計畫名稱
107 貴校生醫材料暨組織工程研究所白台瑞教授申請本部108/109年度本部與法國在臺協會幽蘭計畫-人員交流互訪(第一年)案，業經雙方審查通過核定補助，請查照辦理。
補助單位
計畫名稱
107 評估奈米過濾管柱在細胞治療及再生醫學之應用
補助單位
Asahi Kasei Medical Co., Ltd.
計畫名稱
107 Assessment of Merck’s Bioprocessing Process Efficiency to Clarify, Virus-inactivate, Purify, Deplete of anti-A and anti-B Isoagglutinins, and Concentrate Plasma-Derived Immunoglobulin G
補助單位
台灣默克股份有限公司
計畫名稱
107 探討新穎性血小板奈米囊泡作為遞送神經生物分子載具於腦部再生之應用(1/3)
補助單位
科技部
計畫名稱
106 生醫材料暨組織工程研究所白台瑞教授向本部申請邀請Jean-Pierre Aubert Research Centre David Nathan Blum研究員，於107年03月04日至107年03月09日止來台訪問乙案，本部同意補助其在台日支酬金
補助單位
科技部
計畫名稱
106 以可量產之商用半導體製程建立奈米線場效電晶體血液產品病毒檢測平台 (重點主題:A2)(2/3)
補助單位
科技部
計畫名稱
106 運用血小板及血小板微粒做為癌症藥物載體之研究(3/3)
補助單位
科技部
計畫名稱
105 運用血小板及血小板微粒於再生醫學及移植功能之蛋白質體學分析 (2/2)
補助單位
科技部
計畫名稱
105 默克密理博樹脂純化效率之評估
補助單位
MERCK-MILLIPORE
計畫名稱
105 以可量產之商用半導體製程建立奈米線場效電晶體血液產品病毒檢測平台 (重點主題:A2)(1/3)
補助單位
科技部
計畫名稱
105 運用血小板及血小板微粒做為癌症藥物載體之研究(2/3)
補助單位
科技部
計畫名稱
105 運用血小板及血小板微粒做為癌症藥物載體之研究(2/3)
補助單位
計畫名稱
104 運用血小板及血小板微粒於再生醫學及移植功能之蛋白質體學分析(1/2)
補助單位
科技部
計畫名稱
104 奈米過濾膜移除C型肝炎病毒效能之分析
補助單位
Asahi Kasei Medical Co., Ltd.
計畫名稱
104 運用血小板及血小板微粒做為癌症藥物載體之研究(1/3)
補助單位
科技部
計畫名稱
104 運用血小板及血小板微粒做為癌症藥物載體之研究(1/3)
補助單位
科技部
計畫名稱
104 研究抗體媒介免疫抑制在胎兒及新生兒同種異體免疫性血小板減少症之應用(3/3)
補助單位
科技部
計畫名稱
104 研究抗體媒介免疫抑制在胎兒及新生兒同種異體免疫性血小板減少症之應用(3/3)
補助單位
科技部
計畫名稱
104 米田堡抗原特性之分析(A-103-027)
補助單位
DIAMED GMBH
計畫名稱
103 評估以血小板釋放物擴增培養細胞於再生醫學之應用
補助單位
臺北醫學大學附設醫院
計畫名稱
103 邀請UNIVERSITY OF LIVERPOOL JOHN ALAN HUNT教授，於104年05月19日至104年05月21日來台訪問乙案
補助單位
科技部
計畫名稱
103 生醫材料暨組織工程研究所碩士班研究生翁英然君擬於104年6月赴英國倫敦(LONDON)參加國際輸血研討會，申請補助所需費用乙案
補助單位
科技部
計畫名稱
103 生醫材料暨組織工程研究所碩士班研究生高瑀君君擬於104年6月赴英國倫敦(LONDON)參加第25屆輸血(ISBT)國際協會區域代表大會
補助單位
科技部
計畫名稱
103 研究抗體媒介免疫抑制在胎兒及新生兒同種異體免疫性血小板減少症之應用(2/3)
補助單位
行政院國家科學委員會
計畫名稱
103 人類免疫球蛋白樣品凝血活性之分析
補助單位
NATIONAL INSTITUTES OF HEALTH / USA
計畫名稱
103 在專門設計的單次使用的病毒滅活袋的溶劑/去污劑處理血漿和免疫球蛋白的
補助單位
MERCK-MILLIPORE
計畫名稱
103 利用PLANOVA 75N過濾器移除血小板微粒之分析
補助單位
ASAHI KASEI MEDICAL CO.,LTD
計畫名稱
102 研究抗體媒介免疫抑制在胎兒及新生兒同種異體免疫性血小板減少症之應用(1/3)
補助單位
行政院國家科學委員會
計畫名稱
102 研究抗體媒介免疫抑制在胎兒及新生兒同種異體免疫性血小板減少症之應用(1/3)
補助單位
科技部
計畫名稱
102 研究抗體媒介免疫抑制在胎兒及新生兒同種異體免疫性血小板減少症之應用(2/3)
補助單位
科技部
計畫名稱
102 QSD管柱過濾效果之評估(A-102-083)
補助單位
ASAHI KASEI MEDICAL CO.,LTD
計畫名稱
102 第四屆臺北醫學大學口腔醫學院國際學術研討會-轉譯牙醫學-結合研究與臨床之牙科技術,口腔衛生及基礎研究研討會
補助單位
科技部
計畫名稱
101 血小板微粒特性及功能之體外研究
補助單位
臺北醫學大學附設醫院
計畫名稱
101 血液蛋白質的組份在轉譯治療上的角色與應用
補助單位
行政院國家科學委員會
計畫名稱
101 血液蛋白質的組份在轉譯治療上的角色與應用
補助單位
學校